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Synopsis 29 
 30 
Objectives: This study aimed to compare ESBL-producing Escherichia coli causing 31 
infections in humans with infecting or commensal isolates from animals and isolates 32 
from food of animal origin in terms of the strain types, the ESBL gene present and the 33 
plasmids that carry the respective ESBL genes.  34 
Methods: A collection of 353 ESBL-positive E. coli isolates from the UK, The 35 
Netherlands and Germany was studied by MLST, ESBL gene identification and 36 
characterization of ESBL gene-carrying plasmids by PCR-based replicon typing (PBRT). 37 
Moreover, IncI1-Iγ and IncN plasmids were characterized by plasmid multilocus 38 
sequence typing (pMLST). 39 
Results: The ESBL-producing E. coli represented 158 different STs with ST131, ST10 40 
and ST88 being the most common. Overall, blaCTX-M-1 was the most frequently detected 41 
ESBL gene, followed by blaCTX-M-15, which was the most common ESBL gene in the 42 
human isolates. The most common plasmid replicon type overall was IncI1-Iγ followed 43 
by multiple IncF replicons. 44 
Conclusions: ESBL genes were present in a wide variety of E. coli STs. IncI1-Iγ 45 
plasmids that carried the blaCTX-M-1 gene were widely disseminated amongst STs in 46 
isolates from animals and humans whereas other plasmids and STs appeared to be 47 
more restricted to isolates from specific hosts. 48 
49 
 
 
Introduction 50 
Extended-spectrum cephalosporin antibiotics have been used to treat a variety of 51 
infections caused by Gram-negative bacteria since the 1980s.1 Resistance increased 52 
rapidly during the 2000s due to the dissemination of CTX-M-type enzymes, which are 53 
now the most prevalent ESBLs worldwide. ESBL-carrying Escherichia coli can be 54 
isolated from non-human sources, including companion and food-producing animals. 55 
The potential for ESBL-producing E. coli strains from animals to cause human infections 56 
has long been suggested, but as yet has not been firmly confirmed or refuted.2 Certainly 57 
there is a diverse collection of ESBL genes and E. coli strains amongst animals 58 
globally.3,4 There is potential for this reservoir to affect humans either by direct 59 
transmission of resistant strains or by them serving as donors for horizontal exchange of 60 
plasmids carrying ESBL genes.  61 
This study aimed to investigate the extent of similarities between ESBL-producing 62 
E. coli causing infections in humans and those from animal and food sources in three 63 
European countries. 64 
 65 
 66 
Materials and methods 67 
Isolate selection 68 
A total of 353 E. coli isolates with phenotypic resistance to ampicillin and cefotaxime 69 
(according to EUCAST guidelines)5 were studied from the European ESBL-70 
SAFEFOODERA project collection (EU ERA-Net, Ref. 08176).6 The isolates were 71 
selected from national antimicrobial resistance surveillance programmes or from 72 
participants’ routine diagnostic or reference laboratory activities and isolated between 73 
2005-2009 (Table S1). 74 
 75 
 
 
Plasmid and ESBL characterisation 76 
ESBL and plasmid-mediated AmpC (pAmpC) genes had previously been identified to 77 
family level (e.g. TEM, SHV or CTX-M) and sub-family group (e.g. CTX-M group 1 or 78 
CTX-M group 9) level using a commercial microarray.6 They were further characterised 79 
by PCR and DNA sequencing as described previously.7 80 
Plasmid DNA was extracted from E. coli isolates and transfered into competent 81 
E. coli DH10B cells by electroporation (Life Technologies, Paisley, UK) as described.8 82 
Transformants that had acquired ESBL-encoding plasmids were selected on LB agar 83 
containing 1 mg/L cefotaxime. The replicon types of the ESBL-encoding plasmids were 84 
determined by PCR-based replicon typing (PBRT) as described,9 except that the IncHI2 85 
PCR was performed as a simplex reaction. Additional PCRs were used for IncR, IncU 86 
and ColE plasmids.10 Plasmids belonging to replicon types IncI1-Iγ and IncN were 87 
further characterised using the plasmid multilocus sequence typing (pMLST) schemes 88 
and assigned to plasmid sequence types (pSTs) using the primers and conditions 89 
described on the PubMLST website (http://pubmlst.org/plasmid). 90 
 91 
Molecular characterisation of E. coli strains 92 
Genomic DNA was extracted from E. coli isolates using the Promega Wizard Kit 93 
(Promega, Southampton, UK). MLST was performed using the ‘Achtman scheme’ as 94 
previously described.11 Data were analysed using BioNumerics (Applied Maths v.6.1) 95 
and figures generated using the minimum spanning tree for categorical data tool. 96 
 97 
 98 
Results and discussion 99 
Molecular characterisation of E. coli strains 100 
 
 
MLST identified 158 different STs amongst the 353 ESBL-producing isolates. Fewer STs 101 
were found amongst the 134 ESBL-positive E. coli from humans than amongst the 219 102 
isolates from animals and other sources (52 vs 125, respectively), although this apparent 103 
difference in diversity may have been biased by ‘convenience sampling’ of isolates in the 104 
collection, with no human commensal isolates included in the study. In humans, 44.0% 105 
(59/134) of the isolates belonged to the three most common human STs (ST131, ST405 106 
and ST10/38, Table S2) compared with 34.9% (22/63) of the most common STs in cattle 107 
(ST88, ST69 and ST10) and only 19.7% (27/137) in poultry (ST10, ST88 and ST665). 108 
Overall, the ten most frequently identified STs (131, 10, 88, 405, 117, 58, 69, 38, 665, 109 
156) (Table S2) accounted for 43.9% (155/353)  isolates and eight of these were present 110 
among isolates from both animals and humans; the two exceptions were ST405 111 
(humans only) and ST665 (poultry only). In total, 17 STs were shared by E. coli from 112 
both animals and humans. 113 
Overall, ST131 was the most common ST identified (43 isolates; 12.2%) in this 114 
collection. The majority (40/43) of ST131 isolates were from humans, although three 115 
were from poultry samples (one each from retail meat and caecal contents from The 116 
Netherlands and one from faeces from Germany). The next most common STs were 117 
ST10 (26 isolates; 7.4%) followed by ST88 (23 isolates; 6.5%), both of which were 118 
isolated from a variety of sources in all three countries (Table S2). This result is 119 
supported by previous studies that have shown E. coli ST88 to be globally distributed in 120 
animals and humans12,13 and to a further extent also ST10, 14-16 suggesting that there is 121 
potential that these STs could be circulating between animals and humans. However, 122 
more discriminatory typing via whole genome sequencing would be necessary to confirm 123 
this.17 Other STs seemed to be more host-restricted, although low numbers of 124 
representatives in this collection of some STs prevented robust analysis. For example, 125 
 
 
ST131, ST405 and ST38 appeared to be more frequently found in ESBL-producing 126 
isolates from humans (Table S2).  127 
 128 
ESBL genes and replicon types of ESBL gene-carrying plasmids 129 
Overall, blaCTX-M-1 was the most common ESBL gene (132/353, 37.4%), followed by 130 
blaCTX-M-15 (87/353, 24.6%) (Table 1). The blaCTX-M-1 gene was the most frequent ESBL 131 
gene in poultry isolates (64/137, 46.7%) in all three countries and from cattle in Germany 132 
(22/26, 84.6%) (Table S3). This differs from cattle in the UK where blaCTX-M-15 was most 133 
common (17/34, 50%) (Table S3). The pAmpC gene blaCMY-2 was the second most 134 
frequent cefotaxime resistance gene in poultry isolates from Germany (4/18, 22.2%); 135 
blaTEM-52c in the Netherlands (18/86, 20.9%) and blaCTX-M-14 in the UK (7/33, 21.2%) 136 
(Table S3). The blaCTX-M-15 gene was common in human isolates in all three countries 137 
(67/134 50.0%), although in humans in the Netherlands (19/66, 28.8%) and Germany 138 
(5/14, 35.7%) blaCTX-M-1 was far more frequent than in the UK (2/54, 3.7%) (Table S3). 139 
Transformation of plasmids that conferred cefotaxime resistance into E. coli 140 
DH10B was successful for 341/353 (96.6%) donor isolates. Replicon typing of the 141 
transformed plasmids revealed that IncI1-Iγ plasmids were most common overall 142 
(142/341, 41.6%) (Table 1). The IncI1-Iγ plasmids were widely disseminated among 143 
isolates from different sources and countries although they were predominant in cattle 144 
from the UK and Germany and in humans and poultry from the Netherlands (Table S4).  145 
 146 
Complexity of ST-ESBL gene-plasmid combinations  147 
In this collection of 353 cefotaxime-resistant E. coli from three countries, we identified 148 
158 STs, 16 different ESBL genes or the pAmpC gene blaCMY-2 and 19 different plasmid 149 
replicon types among the 341 transferable plasmids carrying these genes. This 150 
complexity makes it difficult to seek direct evidence for possible overlap between human 151 
 
 
and non-human reservoirs in this collection. Despite the diversity observed, the study 152 
identified a number of dominant E. coli ST-plasmid-ESBL gene combinations, some of 153 
which were found only in isolates from humans, such as ST131 and ST405 with multiple 154 
IncF blaCTX-M-15–carrying plasmids or only in animals, such as ST88 with IncI1-Iγ blaCTX-M-155 
1–carrying plasmids. In contrast, other combinations were found in isolates from all 156 
sources, such as ST10, ST58 and ST117 with IncI1-Iγ plasmids. 157 
Of 142 transformants carrying IncI1-Iγ plasmids 89 (62.7%) were positive for 158 
blaCTX-M-1 (Table 2). The plasmid donor? isolates belonged to 56 different STs, with ST10 159 
(ten isolates plus seven single (SLV) and one triple locus variants (TLV)) and ST88 (ten 160 
isolates plus three SLVs and two double locus variants (DLVs)) being the most common 161 
STs. Analysis of a subset of 128 IncI1-Iγ plasmids by pMLST revealed considerable 162 
diversity. The analysed IncI1-Iγ plasmids were assigned to 16 pMLST types of which 163 
pST7 (43/128, 33.6%) and pST3 (27/128, 21.1%) were the most common as previously 164 
described.18 Plasmids displaying the IncN replicon type (22/341, 6.5%) were associated 165 
with human isolates, with most of them (21/22, 95.5%) harbouring blaCTX-M-1. The pMLST 166 
of the IncN plasmids showed that all represented pST1. The IncK replicon type was 167 
frequent in poultry and meat isolates from all three countries (Table S4), most of these 168 
plasmids carried blaCTX-M-14 (13/24, 54.2%).  169 
Multiple IncF replicons were seen in 56/341 (16.4%) plasmids, and consisted of 170 
eight different rep combinations (Table S5). Five of these combinations were found 171 
exclusively in human isolates, the three others were found in both animal and human 172 
isolates. Plasmids that exhibited IncF alone were present in 10 isolates (10/341 2.9%) 173 
with half of these isolates originating from cattle faecal samples and carrying blaCTX-M-14. 174 
There is potential for plasmid/ESBL gene transmission between E. coli from 175 
humans, animals and food. IncI1-Iγ plasmids harbouring blaCTX-M-1 were common in 176 
animal isolates and were also seen in human E. coli isolates of 56 different STs. Other 177 
 
 
plasmids seemed to be less widely disseminated, such as the multiple IncF blaCTX-M-15-178 
bearing plasmids. These conclusions are supported by data from other national studies 179 
performed on more recent isolates in each of the countries.19,20 In the future, it would be 180 
interesting to further investigate (i) the relatedness of E. coli isolates that shared the 181 
same STs by whole genome sequencing and (ii) the mechanisms by which certain 182 
plasmids are adaptable to multiple hosts/E. coli types while others are seemingly host 183 
restricted.  184 
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Table 1:  Associations between major E. coli sequence types, ESBL genes and ESBL-encoding plasmids 281 
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a Other replicon types Includes; 6 IncHI2, 7 IncB/O, 1 ColE, 1 IncFIA, 3 IncHI2 and? IncP, 2 IncB/O and? IncP and 62 non-identifiable 286 
 287 
b Includes one CTX-M-9 with point mutations at nucleotide 93 (G →T)  and 701 (T→C) which are both synonymous mutations  288 
c 30 isolates had phenotypic resistance to ampicillin and cefotaxime but the gene responsible was not identified 289 
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Table 2: Association of ESBL genes with plasmid replicon types 291 
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